http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Boston Scientific Announces Results For First Quarter 2019
-
Boston Scientific (BSX) Receives FDA Approval for LOTUS Edge Aortic Valve System
-
Boston Scientific Receives FDA Approval for LOTUS Edge™ Aortic Valve System
-
Boston Scientific Announces Conference Call Discussing First Quarter 2019 Financial Results
-
Boston Scientific (BSX) Highlights Positive Safety & Efficacy Data for LUMINIZE RF Balloon Catheter During Late-Breaking Clinical Trial
-
Late-breaking Clinical Trial Highlights Positive Safety and Efficacy Data for the LUMINIZE™ RF Balloon Catheter
-
Boston Scientific Receives CE Mark for Next Generation WATCHMAN FLX™ Left Atrial Appendage Closure Device
-
Boston Scientific Announces Scheduled Data at EHRA 2019 Congress
-
Boston Scientific to Participate in the Cowen and Company 39th Annual Healthcare Conference
-
Boston Scientific to Participate in the 8th Annual SVB Leerink Global Healthcare Conference
-
Boston Scientific Announces Results For Fourth Quarter And Full Year 2018
-
Boston Scientific (BSX) Says New Four-Year Data Demonstrate Rezum Water Vapor Therapy Offers Significant Durable Improvement of BPH Symptoms
-
New Four-Year Data Demonstrate Rezūm™ Water Vapor Therapy Offers Significant Durable Improvement of Benign Prostatic Hyperplasia Symptoms
-
Boston Scientific Launches Vercise™ Primary Cell And Vercise Gevia™ Deep Brain Stimulation Systems With Directional Leads
-
Boston Scientific (BSX) Reports VICI VENOUS STENT System Demonstrates Positive Clinical Outcomes in Patients with Deep Venous Blockages
-
VICI VENOUS STENT® System Demonstrates Positive Clinical Outcomes in Patients with Deep Venous Blockages
-
Boston Scientific (BSX) and Edwards Lifesciences (EW) Agree to Settle Litigation
-
Boston Scientific, Edwards Lifesciences Agree To Global Litigation Settlement
-
Boston Scientific (BSX) Reports In-Line Prelim. Q4 Sales
-
Boston Scientific Announces Preliminary Unaudited Sales for the Fourth Quarter and Full Year 2018
-
Boston Scientific Announces Conference Call Discussing Fourth Quarter 2018 Financial Results And Investor Update At NANS 2019
-
Boston Scientific (BSX) Exercises Option to Acquire Remaining Shares of Millipede
-
Boston Scientific Exercises Option to Acquire Millipede, Inc.
-
Boston Scientific to Participate in 37th Annual J.P. Morgan Healthcare Conference
-
Boston Scientific Prevails in U.S. Edwards Lifesciences Litigation
-
Boston Scientific to Participate in 2018 BMO Capital Markets Prescriptions for Success Healthcare Conference
-
Boston Scientific to Participate in Citi's 2018 Global Healthcare Conference
-
Boston Scientific to Participate in the 30th Annual Piper Jaffray Healthcare Conference
-
Boston Scientific (BSX) Reports Agreement to Purchase BTG Plc. for Approx. $4.2B
-
Boston Scientific Announces Recommended Offer to Acquire BTG plc.
-
Boston Scientific to Participate in 2018 Canaccord Genuity Medical Technologies & Diagnostics Forum
-
Boston Scientific to Participate in Stifel 2018 Healthcare Conference
-
Boston Scientific to Participate in 27th Annual Credit Suisse Healthcare Conference
-
Boston Scientific Announces Results For Third Quarter 2018
-
Edwards Lifesciences (EW) Releases Statement on German Court Decision to Grant Boston Scientific Corp. (BSX) Prelim. Injunction on Edwards SAPIEN 3 Ultra Valve in Germany
-
Boston Scientific (BSX) Says it Prevailed in German Edwards Lifesciences (EW) Litigation
-
Boston Scientific Prevails in German Edwards Lifesciences Litigation
-
Boston Scientific Closes Acquisition of Augmenix, Inc.
-
Boston Scientific Announces Conference Call Discussing Third Quarter 2018 Financial Results
-
Boston Scientific (BSX) Announces FDA Approval for Eluvia Drug-Eluting Vascular Stent System
-
Boston Scientific Receives U.S. FDA Approval for the Eluvia™ Drug-Eluting Vascular Stent System
-
Boston Scientific (BSX) Reports Positive 12-Month Data for Eluvia Drug-Eluting Stent Demonstrates Superior Results in IMPERIAL Trial
-
Boston Scientific Eluvia Drug-Eluting Stent Demonstrates Superior Results In IMPERIAL Trial
-
Boston Scientific Launches LithoVue Empower™ Retrieval Deployment Device
-
Boston Scientific Announces Scheduled Presentations At Transcatheter Cardiovascular Therapeutics 2018
-
Boston Scientific (BSX) to Acquire Augmenix for Up to $600M
-
Boston Scientific Announces Agreement To Acquire Augmenix, Inc.
-
Boston Scientific to Participate in Morgan Stanley Global Healthcare Conference
-
Boston Scientific to Participate in 13th Annual Wells Fargo Securities Healthcare Conference
-
Motus GI Appoints Jeff Hutchison as VP of U.S. Sales and Commercial Operations

